Patient bei Erstvorstellung: CA: 14 Jahre Länge: 145.2 cm (-2.37 SDS, Tanner) Skelettalter: 12.5 Jahre Pubertät: HV 3/3 ml, Gl, Pl (präpubertär) Neurologisch o.B., milde Mikrognathie, Milder Mikrozephalus, BMI 17 kg/m² Geburt: GA: ?, 47 cm, 2.500 g Abbildung mod. nach Domene, 2004
Patient bei Erstvorstellung Labor Wert N-Bereich Serum growth hormone level (ng/ml) Baseline level 4.5 Peak 31.0 > 10.0 Nocturnal 12-hr growth hormone profile Level (ng/ml) 18.9 ± 12.6 4.5 ± 1.4 Amplitude (ng/ml) 16.3 ± 11.0 8.5 ± 4.3 Frequenzy of peaks (per hr) 0.42 0.33 0.08 Serum growth hormone-binding protein level (nM) 1.62 1.10 - 5.50 Abbildung mod. nach Domene, 2004
Responses of the Insulin-like Growth Factor (IGF) Variable Base Line With rhGH Treatment IGF-1 Level (ng/ml) No. of SD below mean 5 Days 39 4.7 7 Days 20 6.3 1 Mo 20 6.3 3 Mo 29 4.4 6 Mo 23 6.0 31 5.3 IGFBP-3 Level (µg/ml) No. of SD below mean 0.22 9,7 0.21 9.9 0.28 8.9 0.27 9.0 0.41 7.6 0.33 8.3 ALS Level (µg/ml) ND ND ND ND ND --- Glucose-tolerance test Insulin level (µU/ml) Base line Peak 120 Min Glucose level (mg/dl) Growth hormone level (ng/ml) 60 Min Ratio of fasting glucose level to insulin level Insulin-sensitivity index Glycosylted hemoglobin (%) 32 260 44 28 237 187 36 308 191 100 145 85 93 155 126 82 156 92 1.9 11.1 3.12 1.53 5.7 4.3 32.0 3.31 1.57 5.6 6.3 3.2 2.27 1.25 5.3 Abbildung mod. nach Domene, 2004